SELLAS Life Sciences Group, Inc. (SLS): Operating Cash Flow
-$28.39M
Year ended 2025-12-31
-$28.42M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$28.39M | n/m | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | -$35.40M | n/m | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | -$31.41M | n/m | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | -$23.81M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$26.02M | n/m | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | -$10.42M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$17.64M | n/m | 2021-03-23, From 2019-01-01 |
| 2018-12-31 | -$30.42M | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$10.99M | n/m | 2019-03-22, From 2017-01-01 |
| 2016-12-31 | -$11.85M | n/m | 2018-04-13, From 2016-01-01 |
| 2015-12-31 | -$48.16M | n/m | 2017-03-15, From 2015-01-01 |
| 2014-12-31 | -$42.87M | n/m | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | -$28.93M | n/m | 2016-04-15, From 2013-01-01 |
| 2012-12-31 | -$20.97M | n/m | 2015-03-05, From 2012-01-01 |
| 2011-12-31 | -$14.67M | n/m | 2014-03-17, From 2011-01-01 |
| 2010-12-31 | -$10.26M | n/a | 2012-03-28, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | 2025-12-31 | -$28.39M | n/m |
| Adagene Inc. (ADAG) | 2025-12-31 | -$15.66M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.93M | n/m |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$44.76M | n/m |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | -$88.63M | n/m |
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | -$12.87M | n/m |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | -$13.38M | n/m |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | -$33.35M | n/m |
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | -$28.55M | n/m |
Compare SLS, ADAG, CPIX, NWBO side by side · Screen every company in Pharmaceutical Preparations ↗